Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE + apatinib + camrelizumab versus TACE for unresectable recurrent hepatocellular carcinoma
ChiCTR2400091246Phase 4Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Rivoceranib and camrelizumab in hepatocellular carcinoma (HCC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400091246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091246.